Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05511831

The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI

ST-segment Elevation Myocardial Infarction (STEMI) Clinical Trial

Official title:
A Randomized Controlled Study on the Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI

Clinical Trial Summary

The purpose of this study was to evaluate the efficacy and safety of ketotifen (MC stabilizer) on the basis of standard treatment after primary PCI in STEMI patients. The ketotifen group and the control group were the ketotifen group and the control group. The control group continued to receive STEMI standard treatment. The ketotifen group received ketotifen for 3 months on the basis of standard treatment within 24 hours after primary PCI, and was followed up for 1 year. Infarct size, as well as differences in echocardiography, markers of two-dimensional speckle tracking, inflammatory factors and MC markers, and major adverse cardiovascular events.

Clinical Trial Description

Percutaneous coronary intervention (PCI) is the best way to improve the prognosis of patients with acute ST-segment elevation myocardial infarction (STEMI). However, STEMI after PCI may still have ischemia-reperfusion injury, inappropriate ventricular remodeling and myocardial fibrosis, which may be related to the inflammatory response of STEMI. Mast cells (MCs) and their degranulation products play an important role in the inflammatory response as well as inducing a series of inflammatory factors. It has been observed in animal experiments that MC stabilizers can improve the ejection fraction, reduce myocardial infarction size and myocardial fibrosis in patients with STEMI, but there is a lack of clinical studies to confirm the role of MC stabilizers in STEMI. The purpose of this study was to evaluate the efficacy and safety of ketotifen (MC stabilizer) on the basis of standard treatment after primary PCI in STEMI patients. The ketotifen group and the control group were the ketotifen group and the control group. The control group continued to receive STEMI standard treatment. The ketotifen group received ketotifen for 3 months on the basis of standard treatment within 24 hours after primary PCI, and was followed up for 1 year. Infarct size, as well as differences in echocardiography, markers of two-dimensional speckle tracking, inflammatory factors and MC markers, and major adverse cardiovascular events, to demonstrate that ketotifen can reduce ischemia-reperfusion injury and improve ventricular reperfusion in AMI. It provides new ideas for the treatment of AMI and a new basis for the optimization of STEMI treatment strategies. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05511831
Study type Interventional
Source Peking University Third Hospital
Contact Ming Cui, Doctor
Phone +8615611908487
Email mingcui@bjmu.edu.cn
Status Not yet recruiting
Phase Phase 4
Start date September 1, 2022
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04962178 - Evaluate Early Invasive Strategy for Patients With STEMI Presenting 24-48 Hours From Symptom Onset N/A
Not yet recruiting NCT04549766 - Predictive Value of PRECISE DAPT Score in STEMI Patients After Primary PCI
Completed NCT05649696 - Prolonged Clinical Follow-up of OPTIMA-5 Phase 4
Recruiting NCT05506449 - The RECOVER IV Trial N/A
Completed NCT01144819 - Platelet Inhibition in the Acute Phase of STEMI N/A
Recruiting NCT03539133 - Systemic Organ Communication in STEMI
Completed NCT01642667 - Pharmacoinvasive Therapy With Prourokinase Phase 2/Phase 3
Completed NCT04131816 - HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program N/A
Recruiting NCT03768453 - EARLY-MYO-CMR Registry
Completed NCT04942977 - Rehabilitation After Acute Coronary Syndrome: a New Telemonitoring Strategy N/A
Recruiting NCT04912518 - Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction N/A
Completed NCT04996901 - The Chinese STEMI PPCI Registry (CSPR)
Recruiting NCT05892042 - Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction N/A
Completed NCT02197117 - Effect of Remote Ischemic Conditioning in Heart Attack Patients N/A
Completed NCT02733341 - The Effect of IV Cangrelor and Oral Ticagrelor Study Phase 4
Not yet recruiting NCT04110691 - Impact of Stent Length and Diameter on Patients Undergoing Primary PCI
Recruiting NCT05510661 - Use of Export in Primary Percutaneous Coronary Intervention N/A
Recruiting NCT05709626 - PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction Phase 4
Recruiting NCT05046483 - Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
Active, not recruiting NCT04828681 - Angio-IMR and Cardiac MR-derived MVO in STEMI Patients